keyword
MENU ▼
Read by QxMD icon Read
search

Second line therapy type 2 diabetes metformin

keyword
https://www.readbyqxmd.com/read/27875596/cost-effectiveness-of-saxagliptin-versus-acarbose-as-second-line-therapy-in-type-2-diabetes-in-china
#1
Shuyan Gu, Yuhang Zeng, Demin Yu, Xiaoqian Hu, Hengjin Dong
OBJECTIVE: This study assessed the long-term cost-effectiveness of saxagliptin+metformin (SAXA+MET) versus acarbose+metformin (ACAR+MET) in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on MET alone. METHODS: Systematic literature reviews were performed to identify studies directly comparing SAXA+MET versus ACAR+MET, and to obtain diabetes-related events costs which were modified by hospital surveys. A Cardiff Diabetes Model was used to estimate the long-term economic and health treatment consequences in patients with T2DM...
2016: PloS One
https://www.readbyqxmd.com/read/27827311/comparative-effectiveness-of-second-line-agents-for-the-treatment-of-diabetes-type-2-in-preventing-kidney-function-decline
#2
Adriana M Hung, Christianne L Roumie, Robert A Greevy, Carlos G Grijalva, Xulei Liu, Harvey J Murff, T Alp Ikizler, Marie R Griffin
BACKGROUND AND OBJECTIVES: Diabetes is the leading cause of ESRD. Glucose control improves kidney outcomes. Most patients eventually require treatment intensification with second-line medications; however, the differential effects of those therapies on kidney function are unknown. DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: We studied a retrospective cohort of veterans on metformin monotherapy from 2001 to 2008 who added either insulin or sulfonylurea and were followed through September of 2011...
November 8, 2016: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/27809608/an-update-on-dpp-4-inhibitors-in-the-management-of-type-2-diabetes
#3
Avivit Cahn, Simona Cernea, Itamar Raz
DPP-4 inhibitors are a class of compounds used for the treatment of type 2 diabetes. The drugs inhibit the degradation of GLP-1, thus amplifying the incretin effect. They have moderate glycemic efficacy, a low propensity of causing hypoglycaemia and are weight neutral. The drugs are often used as second line therapy after metformin. Areas covered: This review summarizes the available compounds in the market and discusses the novel compounds that are currently under development. Several large cardiovascular outcome trials with some of the compounds have been completed, and their results and implications are considered...
November 4, 2016: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/27752788/the-place-of-dpp-4-inhibitors-in-the-treatment-algorithm-of-diabetes-type-2-a-systematic-review-of-cost-effectiveness-studies
#4
Alexandre Baptista, Inês Teixeira, Sónia Romano, António Vaz Carneiro, Julian Perelman
OBJECTIVE: To conduct a systematic review of cost-effectiveness, cost-utility, and cost-benefit studies of DPP-4 inhibitors for diabetes treatment versus other antidiabetics. METHODS: Three investigators searched the CRD York, Tufts CEA Registry, and MEDLINE databases through 2015. We reviewed all potentially relevant titles and abstracts, and screened full-text articles, according to inclusion criteria. We established a quality score for each study based on a 35-item list...
October 17, 2016: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/27649712/-sodium-glucose-cotransporter-2-sglt-2-inhibitors-for-patients-with-type-2-diabetes
#5
Michael Einar Røder, Heidi Storgaard, Jørgen Rungby, Filip Krag Knop, Tina Vilsbøll
The sodium-glucose cotransporter 2 inhibitor (SGLT-2i)-class is efficacious as monotherapy and as add-on therapy with an expected lowering of the glycated haemoglobin (HbA1c) concentration of approximately 7 mmol/mol. Side effects relate to the mode of action, genital infections are the main problem. Extremely rare cases of ketoacidosis are reported, mostly in patients with Type 1 diabetes. One SGLT-2i, empagliflozin, has been shown to reduce cardiovascular mortality and progression of kidney disease in patients with Type 2 diabetes and cardiovascular disease...
September 19, 2016: Ugeskrift for Laeger
https://www.readbyqxmd.com/read/27466703/omarigliptin-for-the-treatment-of-type-2-diabetes-mellitus
#6
Philip M S Evans, Stephen C Bain
INTRODUCTION: The estimated global prevalence of diabetes mellitus for adults aged 20-70 in 2015 was 415 million with approximately 90% of diagnosed cases being Type 2 diabetes mellitus (T2DM). Improvements in lifestyle and effective therapies are key to management but due to the progressive nature of T2DM, pharmacotherapy is typically required. Whilst the initial therapy will usually be with metformin, thereafter treatment should be individualised, with consideration of several different second line options...
October 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27376699/differences-in-glycemic-control-across-world-regions-a-post-hoc-analysis-in-patients-with-type-2-diabetes-mellitus-on-dual-antidiabetes-drug-therapy
#7
H Brath, P M Paldánius, G Bader, W M Kolaczynski, P M Nilsson
OBJECTIVE: This post-hoc analysis of the EDGE (Effectiveness of Diabetes control with vildaGliptin and vildagliptin/mEtformin) study assessed inter-regional differences in baseline characteristics and response to treatment intensification with dual oral antidiabetes drugs (OADs) in patients with type 2 diabetes mellitus (T2DM). METHODS: Patients with T2DM inadequately controlled with first-line monotherapy were assigned to receive a dipeptidyl peptidase-4 (DPP-4) inhibitor, vildagliptin, or comparator OADs as add-on dual therapy...
2016: Nutrition & Diabetes
https://www.readbyqxmd.com/read/27350752/sglt2-inhibitors-or-glp-1-receptor-agonists-as-second-line-therapy-in-type-2-diabetes-patient-selection-and-perspectives
#8
REVIEW
Holly E Gurgle, Karen White, Carrie McAdam-Marx
Controversy exists regarding the selection of second-line therapy for patients with type 2 diabetes mellitus (T2DM) who are unable to achieve glycemic control with metformin therapy alone. Newer pharmacologic treatments for T2DM include glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Both the classes of medication are efficacious, exhibit positive effects on weight, and are associated with minimal risk of hypoglycemia. The purpose of this review is to compare the clinical trial and real-world effectiveness data of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors related to A1c reduction, weight loss, cost-effectiveness, cardiovascular outcomes, and safety in patients with T2DM...
2016: Vascular Health and Risk Management
https://www.readbyqxmd.com/read/27182828/role-of-metformin-in-women-s-health-review-of-its-current-place-in-clinical-practice-and-emerging-indications-for-future
#9
Vikram Sinai Talaulikar, Thomas Tang, Ephia Yasmin
IMPORTANCE: Metformin, an oral antihyperglycemic drug, acts as an insulin sensitizer in the treatment of type 2 diabetes mellitus. It has also been widely used in the treatment of polycystic ovary syndrome (PCOS) and gestational diabetes mellitus. Although randomized clinical trials have failed to establish its superiority over other forms of treatment, metformin continues to be a treatment option in specific subgroups of women either alone or as an adjunct with other therapies in management of PCOS...
May 2016: Obstetrical & Gynecological Survey
https://www.readbyqxmd.com/read/27177784/comparative-risk-of-major-cardiovascular-events-associated-with-second-line-antidiabetic-treatments-a-retrospective-cohort-study-using-uk-primary-care-data-linked-to-hospitalization-and-mortality-records
#10
S S Zghebi, D T Steinke, M K Rutter, R A Emsley, D M Ashcroft
AIMS: To examine the risk of major cardiovascular events associated with second-line diabetes therapies, in patients with type 2 diabetes, after adjusting for known cardiovascular risk factors. METHODS: This was a retrospective cohort study of patients prescribed second-line regimens between 1998 and 2011 after first-line metformin. The UK Clinical Practice Research Datalink, with linked national hospitalization and mortality data, for the period up to December 2013, was used...
September 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27123911/hypoglycemia-incidence-rates-and-associated-health-care-costs-in-patients-with-type-2-diabetes-mellitus-treated-with-second-line-linagliptin-or-sulfonylurea-after-metformin-monotherapy
#11
Aditya Raju, Sharash Shetty, Beilei Cai, Anna O D'Souza
BACKGROUND: Hypoglycemia poses a significant clinical and economic burden to patients with type 2 diabetes mellitus (T2DM). Minimizing the risk of hypoglycemia is an important component when managing patients with T2DM. Understanding hypoglycemia rates and the associated economic consequences can help to inform health care decision makers. OBJECTIVE: To assess hypoglycemia incidence rates and associated costs in patients who initiated second-line treatment with the antidiabetic agents linagliptin or a sulfonylurea (SU) after metformin...
May 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27062643/change-in-glycated-haemoglobin-levels-after-initiating-second-line-therapy-in-type-2-diabetes-a-primary-care-database-study
#12
W Rathmann, B Bongaerts, K Kostev
The aim of the present study was to compare the absolute reduction in glycated haemoglobin (HbA1c) levels at 6 months after initiating second-line glucose-lowering therapy in patients with type 2 diabetes treated with metformin monotherapy in general practices. A total of 7009 patients were identified (Disease Analyser Germany: January 2004 to December 2014). The patients' mean ± standard deviation (s.d.) age was 63 ± 11 years, 55.5% were male and their mean ± s.d. HbA1c level was 8.0 ± 1.6%. The initiated second-line therapies included: dipeptidyl peptidase-4 (DPP-4) inhibitors (38...
August 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27040861/safety-and-efficacy-of-dipeptidyl-peptidase-4-inhibitors-vs-sulfonylurea-in-metformin-based-combination-therapy-for-type-2-diabetes-mellitus-systematic-review-and-meta-analysis
#13
Naghmeh Foroutan, Sergei Muratov, Mitchell Levine
PURPOSE: The purpose of this study was to compare the safety and efficacy of DPP-4 inhibitors versus sulfonylurea as adjunctive second-line therapy in patients with type 2 diabetes mellitus, inadequately controlled with metformin mono-therapy. SOURCES: A systematic review of published randomized controlled trials (RCTs) was performed in MEDLINE, EMBASE, PubMed and Cochrane library. Two reviewers independently selected the studies, extracted the data and assessed the risk of bias...
2016: Clinical and Investigative Medicine. Médecine Clinique et Experimentale
https://www.readbyqxmd.com/read/26982210/important-differences-in-the-durability-of-glycaemic-response-among-second-line-treatment-options-when-added-to-metformin-in-type-2-diabetes-a-retrospective-cohort-study
#14
Jil Mamza, Rajnikant Mehta, Richard Donnelly, Iskandar Idris
IMPORTANCE: There is limited information about the durability of glycaemic control when different oral glucose-lowering therapies (GLTs) are used as add-on treatments to metformin (MET) in patients with type 2 diabetes mellitus (T2DM). OBJECTIVE: To compare time to treatment failure between different classes of oral GLT when used as second line (add-on) treatments to MET monotherapy at HbA1c ≥ 7.5%. DESIGN, SETTING AND PARTICIPANTS: A retrospective cohort study on 20,070 patients who were newly treated with a sulphonylurea (SU), dipeptidyl-peptidase-4 (DPP-4) inhibitor or thiazolidinedione (TZD) following MET therapy failure (2007-2014)...
2016: Annals of Medicine
https://www.readbyqxmd.com/read/26907851/consequences-of-delaying-treatment-intensification-in-type-2-diabetes-evidence-from-a-uk-database
#15
Louise Watson, Romita Das, Ruth Farquhar, Haya Langerman, Anthony H Barnett
OBJECTIVE: Type 2 diabetes mellitus (TD2M) treatment focuses on achieving glycemic control, with HbA1c targeted at 6.5-7.5%. Clinicians commonly delay treatment intensification despite patients failing glycemic targets. This study evaluated longitudinal clinical and cost outcomes in patients failing metformin monotherapy using electronic medical records. RESEARCH DESIGN AND METHODS: Adults with incident T2DM were identified in the UK Clinical Practice Research Datalink (CPRD) from 1 January 2000 to 31 March 2014...
September 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/26890317/comparison-of-use-of-diabetic-medication-and-clinical-guidelines-in-four-nordic-countries
#16
Saara Järvinen, Merja K Laine, Johan G Eriksson
BACKGROUND: Clinical guidelines form one of the cornerstones for providing high-quality care for patients with diabetes. We compare the national guidelines and the use of glucose lowering medication for type 2 diabetes (T2D) in Denmark, Finland, Norway and Sweden. METHODS: We compared how guidelines take comprehensive care into consideration, what treatment targets and what antihyperglycemic medication was recommended. The use of glucose-lowering medication was based on the sales of diabetes drugs in these countries...
2016: Annals of Medicine
https://www.readbyqxmd.com/read/26652788/-clinical-importance-of-basal-insulin-analogues-and-insulin-toujeo%C3%A2-300%C3%A2-units-ml
#17
REVIEW
Alena Adamíková
Type 2 diabetes mellitus is a heterogeneous disease that requires a personalized approach to treatment with goals tailored to capabilities and abilities of the patient, his other diseases so as to ensure good diabetes control without the risk of hypoglycemic events and the development or progression of late diabetic complications. Recommendations for treatment of diabetes is classified in second-line as a one of the possibilities of treatment of basal insulin immediately after the failure of therapy with metformin and diet...
November 2015: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/26597596/comparative-review-of-dipeptidyl-peptidase-4-inhibitors-and-sulphonylureas
#18
REVIEW
C F Deacon, H E Lebovitz
Type 2 diabetes (T2DM) is a progressive disease, and pharmacotherapy with a single agent does not generally provide durable glycaemic control over the long term. Sulphonylurea (SU) drugs have a history stretching back over 60 years, and have traditionally been the mainstay choice as second-line agents to be added to metformin once glycaemic control with metformin monotherapy deteriorates; however, they are associated with undesirable side effects, including increased hypoglycaemia risk and weight gain. Dipeptidyl peptidase (DPP)-4 inhibitors are, by comparison, more recent, with the first compound being launched in 2006, but the class now globally encompasses at least 11 different compounds...
April 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/26532156/comparative-effectiveness-on-cardiovascular-outcomes-of-metformin-initial-therapy-and-add-on-second-line-drugs-among-patients-with-type-2-diabetes
#19
Y Kim, M Ko, A Jo, S Kang, H Tchoe, C Park, H Kim, J Choi, D Park, W Lee
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/26445623/what-s-next-after-metformin-focus-on-sulphonylurea-add-on-or-combination-therapy
#20
REVIEW
Phei C Lim, Chee P Chong
INTRODUCTION: The pathophysiology of type 2 diabetes (T2DM) mainly focused on insulin resistance and insulin deficiency over the past decades. Currently, the pathophysiologies expanded to ominous octet and guidelines were updated with newer generation of antidiabetic drug classes. However, many patients had yet to achieve their target glycaemic control. Although all the guidelines suggested metformin as first line, there was no definite consensus on the second line drug agents as variety of drug classes were recommended...
April 2015: Pharmacy Practice
keyword
keyword
64586
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"